On Monday, U.S. Stocks climbed, bouncing back from Friday’s selloff, following shareholders kept on to struggle with the outlook of higher interest rates.
According to Wallstreet Journal, The Dow Jones Industrial Average gained 112 points, or 0.6%, to 17969, while the S&P 500 index advanced four points, or 0.2%, to 2076. The Nasdaq Composite Index eased two points to 4926.
Following U.S. Stocks are among the “Top Gainers” during Current trade: RMG Networks Holding Corporation (NASDAQ:RMGN), RTI International Metals, (NYSE:RTI), Asterias Biotherapeutics, (NYSE:AST), Recro Pharma, (NASDAQ:REPH)
Their insights are depicted underneath:
RMG Networks Holding Corporation (NASDAQ:RMGN), skyrocketed 37.14% and is now trading at $1.43.
According to Marketwired, RMG Networks Holding Corporation (RMGN), or RMG Networks, a leading provider of technology-driven visual communications solutions, declared preliminary financial results for its fourth quarter and full year ended December 31, 2014.
Fourth quarter 2014 adjusted proceed is predictable to be about $18.6 million and full year 2014 adjusted proceed is predictable to be about $61.8 million. In addition, the corporation anticipates fourth quarter 2014 adjusted EBITDA to improve sequentially over the third quarter of 2014.
Both of the corporation’s business units are predictable to show strong sequential fourth quarter adjusted proceed growth. In its Enterprise and Media businesses, fourth quarter adjusted proceed is predictable to be $13.1 million and $5.5 million, respectively. These preliminary financial results are subject to completion of the corporation’s customary year-end closing and review procedures and audit by the corporation’s independent registered public accounting firm.
Robert Michelson, Chief Executive Officer, commented, “We executed well in the fourth quarter and our results are encouraging as we expect strong sequential growth in both adjusted proceed and adjusted EBITDA. In addition, we continued to successfully implement the planned initiatives that we expect will further establish the platform for long-term success.”
These preliminary results are being offered ahead of the corporation’s planned presentation at the 27th Annual ROTH Conference so that administration can talk about updated financial information with the investment community. The Corporation undertakes no obligation to issue preliminary results in the future.
RMG Networks will release its full financial results for the fourth quarter and full-year 2014 before the market opens on Thursday, March 19, 2015. Administration will host a conference call to talk about these results on Thursday, March 19, 2015 at 9 a.m. ET.
RMG Networks (NASDAQ: RMGN) assists brands and organizations communicate more effectively using location-based video networks. The corporation builds enterprise video networks that empower organizations to visualize critical data to better run their business.
RTI International Metals, Inc. (NYSE:RTI), climbed nearly 38.71% and is now trading at $37.83, hitting new 52-week high of $38.87.
According to BUSINESS WIRE, Lightweight, high-performance metals leader Alcoa (AA) is announcing another major milestone in its transformation, further building its value-add portfolio for profitable growth. The Corporation has signed a definitive contract to attain RTI International Metals, Inc. (RTI), a global supplier of titanium and specialty metal products and services for the commercial aerospace, defense, energy and medical device markets. Alcoa will purchase RTI in a stock-for-stock transaction with an enterprise value of $1.5 billion.
With RTI, Alcoa will grow its value-add businesses and further strengthen its aerospace portfolio. RTI will expand Alcoa’s range of titanium offerings and add advanced technologies and materials, increasing the Corporation’s position as a leading industrial innovator.
“Alcoa is accelerating its value-add growth engine by acquiring titanium leader RTI,” said Klaus Kleinfeld, Alcoa Chairman and Chief Executive Officer. “We are combining two innovators in materials science and process technology, shifting Alcoa’s transformation into a higher gear. RTI expands our aerospace portfolio market reach and positions us to capture future growth to deliver compelling value for customers, shareholders and employees.”
Under the terms of the contract, Alcoa will attain all outstanding shares of RTI in a stock-for-stock transaction. RTI shareholders will receive 2.8315 Alcoa shares for each RTI share, representing a value of $41 per RTI share based on Alcoa’s closing price on March 6, 2015. The transaction has an enterprise value of $1.5 billion, counting $330 million of RTI cash on hand and up to $517 million in RTI’s convertible notes.
A global leader in lightweight metals technology, engineering and manufacturing, Alcoa innovates multi-material solutions that advance our world.
RTI International Metals, Inc. is a leading vertically integrated global supplier of advanced titanium and specialty metal products and services to commercial aerospace, defense, energy, medical device and other customers across the entire supply chain.
Asterias Biotherapeutics, Inc. (NYSE:AST), inclined 28.57% and is now trading at $6.12.
According to PRNewswire, Asterias Biotherapeutics, Inc. (AST), a leading biotechnology corporation in the emerging field of regenerative medicine, declared that Atlanta-based Shepherd Center, one of the nation’s top rehabilitation hospitals for spinal cord injury and brain injury, has commenced enrollment for the Phase 1/2a clinical trial of AST-OPC1 (oligodendrocyte progenitor cells) in newly injured patients with sensory and motor complete cervical spinal cord injury (SCI).
The Phase 1/2a trial follows the successful completion of the Phase 1 trial of AST-OPC1, which met its primary endpoints of safety and feasibility when administered to five patients with neurologically complete, thoracic SCI. Shepherd Center was a site in the Phase 1 study and enrolled two of the five subjects in that study. Asterias intends to initiate enrollment for the Phase 1/2a trial at up to seven additional sites in the coming months.
“The Phase 1 study generated a strong package of data regarding the safety of AST-OPC1,” said Donald Peck Leslie, M.D., medical director of Shepherd Center and principal investigator for this study site. “With the Phase 1/2a clinical trial, we are excited to start testing AST-OPC1 at the doses and in the population where it has the maximum potential to bring benefit to patients.”
Richard G. Fessler, MD, PhD, professor of neurological surgery at Rush University Medical Center and principal investigator for the Phase 1 clinical trial, said, “There are presently no FDA-approved therapeutics or devices for the more than 12,000 individuals who sustain an SCI each year in the United States alone, or for the about 1.3 million Americans who are estimated to be living with an SCI. If AST-OPC1 could deliver even modest improvements in motor or sensory function, it would result in noteworthy improvements in quality of life.”
The Phase 1/2a clinical trial is designed to assess safety and activity of escalating doses of AST-OPC1 for complete cervical SCI, the first targeted indication for AST-OPC1. The trial will be an open-label, single-arm study testing three escalating doses of AST-OPC1 in patients with sub-acute, C-5 to C-7, neurologically complete cervical SCI. These individuals have essentially lost all sensation and movement below their injury site with severe paralysis of the upper and lower limbs. AST-OPC1 will be administered 14 to 30 days post-injury. Patients will be followed by neurological exams and imaging methods to assess the safety and activity of the product.
Asterias Biotherapeutics, Inc. (NYSE MKT: AST) is a leading biotechnology corporation in the emerging field of regenerative medicine. The Corporation’s core technologies center on pluripotent stem cells, which are characterized by the ability to become all cell types in the human body. Asterias is focused on developing therapies based on pluripotent stem cells to treat diseases or serious injuries in several medical areas where there is high unmet medical need and without adequate accessible therapies.
Recro Pharma, Inc. (NASDAQ:REPH), surged 32.32% and is now trading at $4.35.
According to GLOBE NEWSWIRE, Recro Pharma, Inc. (REPH), declared a definitive contract under which Recro Pharma will attain assets from Alkermes plc counting worldwide rights to IV/IM meloxicam, a proprietary, Phase III-ready, long-acting COX-2 NSAID for moderate to severe acute pain, in addition to a contract manufacturing facility, royalty and formulation business in Gainesville, GA.
Under the terms of the contract, Recro Pharma will pay Alkermes $50 million at closing, and gain the rights to IV/IM meloxicam and ownership of a GMP manufacturing facility and related business located in Gainesville, GA. Alkermes is entitled to receive up to an additional $120 million in milestone payments upon the achievement of certain regulatory and net sales milestones and royalties, in each case, related to IV/IM meloxicam. At closing, Recro Pharma will issue Alkermes a seven-year warrant to purchase an aggregate of 350,000 shares of Recro Pharma ordinary stock. The $50 million up-front payment will be funded via a five-year senior secured term loan with an associate of OrbiMed (“OrbiMed”). The attainment is subject to customary closing conditions, counting antitrust regulatory approval, and is anticipated to close in the second quarter of 2015.
Recro Pharma is a clinical stage specialty pharmaceutical corporation developing non-opioid therapeutics for the treatment of acute post operative pain. Recro Pharma’s lead product candidate, Dex-IN, is a proprietary intranasal formulation of dexmedetomidine and has accomplished multiple clinical trials in which Dex-IN was well tolerated.
